Alliance Global Partners initiated coverage on shares of IGC Pharma (NYSEAMERICAN:IGC – Free Report) in a research note published on Wednesday morning, MarketBeat reports. The brokerage issued a buy rating and a $3.50 price objective on the construction company’s stock.
IGC has been the topic of a number of other reports. StockNews.com started coverage on IGC Pharma in a research note on Monday, May 6th. They issued a sell rating on the stock. Ascendiant Capital Markets reissued a buy rating and issued a $3.25 target price on shares of IGC Pharma in a research report on Friday, June 21st.
Check Out Our Latest Research Report on IGC Pharma
IGC Pharma Stock Performance
IGC Pharma (NYSEAMERICAN:IGC – Get Free Report) last issued its quarterly earnings results on Monday, June 24th. The construction company reported ($0.04) earnings per share for the quarter. The business had revenue of $0.30 million for the quarter. IGC Pharma had a negative return on equity of 119.06% and a negative net margin of 966.54%.
About IGC Pharma
IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.
See Also
- Five stocks we like better than IGC Pharma
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Is This Telehealth Stock a Buy After the Recent Pullback?
- How to Use the MarketBeat Dividend Calculator
- Safeguard Against Credit Card Risks with This Top Financial Stock
- Using the MarketBeat Stock Split Calculator
- Streaming Titan’s Stock Ready to Hit All-Time Highs This Year
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.